 CAMBRIDGE, Mass.--BUSINESS WIRE--Scholar Rock NASDAQ: SRRK, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs. Company Updates and Upcoming Milestones Apitegromab is a selective inhibitor of myostatin activation being developed as the potenti 